

18th Meeting of the European Association
for Haematopathology

EAHP 2016

BASEL · SWITZERLAND | SEPTEMBER 3–8

PROGRAM

Table of Contents

Committees	2
Welcome Address	3
Program at a Glance	4
Scientific Program	
▪ Saturday, September 3, 2016	8
▪ Sunday, September 4, 2016	10
▪ Monday, September 5, 2016	13
▪ Tuesday, September 6, 2016	17
▪ Wednesday, September 7, 2016	21
▪ Thursday, September 8, 2016	23
Poster Presentations	24
Acknowledgement	47
Sponsored Satellite Symposia	48
Networking Dinner	50
General Information	51
Travel Information	54
Map of Basel	55
Overview Conference Venue	56
List of Exhibitors	57

Committees

Chair, Local Organizing Committee

Stephan Dirnhofer, MD
Department of Pathology
Universitätsspital Basel
Basel, Switzerland

Yara Banz, Bern
Sergio Cogliatti, St. Gallen
Esther Garamvölgyi, Marly
Eugenia Haralambieva, Zuerich
Sylvia Höller, Basel
Laurence de Leval, Lausanne
Alexandar Tzankov, Basel
Philip Went, Basel

Executive Committee

Pierre Brousset, France
Elias Campo, Spain
Christiane Copie-Bergman, France
Daphne de Jong, The Netherlands
Stephan Dirnhofer, Switzerland
Marja-Liisa Karjalainen, Finland
Marsha C. Kinney, United States
Isinsu Kuzu, Turkey
German Ott, Germany
Maurilio Ponzoni, Italy
Leticia Quintanilla-Fend, Germany
Birgitta Sander, Sweden
Jon van der Walt, United Kingdom
Andrew Wotherspoon, United Kingdom

Lymphoma Workshop Panel Members

Christiane Copie-Bergman, France
Laurence de Leval, Switzerland
Stephan Dirnhofer, Switzerland
Fabio Facchetti, Italy
Falko Fend, Germany
Stefania Pittaluga, USA

Stefano Pileri, Italy
Andreas Rosenwald, Germany
Lisa Rimsza, USA
Andrew Wotherspoon, United Kingdom

Bone Marrow Workshop Panel Members

Umberto Gianelli, Italy
Konnie Hebeda, Netherlands
Marcus Kremer, Germany
Roos Leguit, Netherlands
Attilio Orazi, USA
Alexandar Tzankov, Switzerland
Jon van der Walt, United Kingdom

Legal Organizer (PCO)

MCI Deutschland GmbH
MCI – Berlin Office
Markgrafenstrasse 56
10117 Berlin, Germany
Phone: +49 30 20 45 90
Fax: +49 30 20 45 950
eahp@mci-group.com

Project Management

Vivien Lietze / Mandy Pekar
eahp@mci-group.com

Registration and Accommodation

registration.berlin@mci-group.com

Industrial Exhibition, Symposia and Sponsoring

Gino Thiel
eahp-sponsoring@mci-group.com

Welcome Address

On behalf of the European Association for Haematopathology (EAHP) and the Society for Hematopathology (SH) it is our pleasure as Chairman of the Local Organizing Committee and President of the EAHP to welcome you to the 18th meeting of the EAHP in Basel. The Executive Committee of the EAHP, with the European Bone Marrow Working Group have put together a comprehensive program addressing “What causes aggressive behaviour” with a focus on genetic changes, micro-environment interactions and deregulation of signalling pathways.

The meeting will start on Saturday with the thymus symposium organized by Prof. Alexander Marx. Following the opening ceremony, the educational session will cover the major changes of the updated WHO-classification of haematolymphoid neoplasms.

The bone marrow symposium and workshop will be devoted to “aggressive malignancies of the “other cells” of the bone marrow: histiocytes, dendritic cells and mast cells”.

The EAHP lymphoma symposium will combine key note and topic lectures by distinguished speakers and oral presentations which have been selected among more than 130 abstracts. There will also be a session for poster discussion. More highlights will be the Karl Lennert lecture on Monday and the David Mason lecture on Tuesday.

The symposium will be followed by the workshop devoted to aggressive lymphoid and accessory/histiocytic cell neoplasms. Around 200 very interesting and challenging cases were received, illustrating the broad spectrum of these disorders. I also would like to draw your attention to the very popular early morning “Meet the Professor” sessions, featuring interaction between the professor and a limited number of attendees.

Last but not least, Basel is a very enjoyable city, in particular in early September. I hope that you will find the time to meet colleagues, discover the old medieval town and visit a few of the more than 30 museums – many of them world class! The social events, a welcome reception at the congress centre and the congress networking dinner in the Markthalle complement the program.

We wish you a stimulating and memorable meeting in Basel.



Stephan Dirnhofer
*Chair, Local
Organizing Committee*

Andrew Wotherspoon
President EAHP



Program at a Glance

	SATURDAY September 03, 2016	SUNDAY September 04, 2016	MONDAY September 05, 2016
7.15 am		MEET THE PROFESSOR	MEET THE PROFESSOR
7.30 am			
7.45 am			
8.00 am		8.25-8.30 INTRODUCTION	
8.15 am		BONE MARROW SYMPOSIUM I	KEYNOTE LECTURE Riccardo Dalla-Favera (New York, USA)
8.30 am			LYMPHOMA SYMPOSIUM I
8.45 am			
9.00 am			
9.15 am			
9.30 am			
9.45 am			
10.00 am		COFFEE BREAK POSTER VIEWING	COFFEE BREAK
10.15 am		BONE MARROW SYMPOSIUM II	KEYNOTE LECTURE Michele Ghilmini (Bellinzona, Switzerland)
10.30 am			LYMPHOMA SYMPOSIUM II
10.45 am			
11.00 am			
11.15 am			Topic Lecture Dan Arber (Stanford, CA, USA)
11.30 am			
11.45 am			
12.00 pm		LUNCH BREAK POSTER VIEWING	LUNCH BREAK POSTER VIEWING
12.15 pm			
12.30 pm			
12.45 pm			
1.00 pm	THYMUS SYMPOSIUM Highlights of thymus pathology	BONE MARROW WORKSHOP I	SATELLITE SYMPOSIA
1.15 pm			
1.30 pm			
1.45 pm			
2.00 pm			
2.15 pm			

Program at a Glance

TUESDAY September 06, 2016	WEDNESDAY September 07, 2016	THURSDAY September 08, 2016	
MEET THE PROFESSOR			7.15 am
			7.30 am
			7.45 am
		LYMPHOMA WORKSHOP IV	8.00 am
			8.15 am
KEYNOTE LECTURE Ralf Küppers (Essen, Germany)	LYMPHOMA SYMPOSIUM VII Topic Lecture Richard Rosenquist (Uppsala, Sweden)		8.30 am
LYMPHOMA SYMPOSIUM IV Topic Lecture James Cook (Cleveland, USA)			8.45 am
			9.00 am
			9.15 am
			9.30 am
	9.45 am		
COFFEE BREAK		COFFEE BREAK	10.00 am
			10.15 am
POSTER SESSION	COFFEE BREAK	LYMPHOMA WORKSHOP V	10.30 am
			10.45 am
			11.00 am
	LYMPHOMA WORKSHOP I		11.15 am
			11.30 am
			11.45 am
LYMPHOMA SYMPOSIUM V Topic Lecture German Ott (Stuttgart, Germany)			12.00 pm
		12.15 pm	
LUNCH BREAK		LUNCH BREAK	12.30 pm
	LUNCH BREAK		12.45 pm
			1.00 pm
SATELLITE SYMPOSIA			1.15 pm
			1.30 pm
		LYMPHOMA WORKSHOP II	1.45 pm
			2.00 pm
			2.15 pm

Program at a Glance

	SATURDAY September 03, 2016	SUNDAY September 04, 2016	MONDAY September 05, 2016	
2.30 pm	THYMUS SYMPOSIUM Highlights of thymus pathology	BONE MARROW WORKSHOP / SESSION I & II	COFFEE BREAK	
2.45 pm				
3.00 pm	OPENING SESSION		KEYNOTE LECTURE Reiner Siebert (Ulm, Germany)	
3.15 pm				
3.30 pm	EDUCATIONAL SESSION Updated WHO-classification of hematolymphoid neoplasms			LYMPHOMA SYMPOSIUM III
3.45 pm				
4.00 pm			COFFEE BREAK	KARL LENNERT LECTURE
4.15 pm				
4.30 pm			BONE MARROW WORKSHOP / SESSION III	
4.45 pm				EBMWG BUSINESS MEETING
5.00 pm				
5.15 pm				
5.30 pm		SATELLITE SYMPOSIA	SATELLITE SYMPOSIA	
5.45 pm				
6.00 pm				
6.15 pm				
6.30 pm	SATELLITE SYMPOSIA	SATELLITE SYMPOSIA		
6.45 pm				
7.00 pm				
7.15 pm	WELCOME RECEPTION			
7.30 pm				
7.45 pm				
8.00 pm				
8.15 pm				
8.30 pm				
8.45 pm				
9.00 pm				

Program at a Glance

TUESDAY September 06, 2016	WEDNESDAY September 07, 2016	THURSDAY September 08, 2016	
LYMPHOMA SYMPOSIUM VI Topic Lecture Fabio Facchetti (Brescia, Italy)	LYMPHOMA WORKSHOP II	LYMPHOMA WORKSHOP VI	2.30 pm
			2.45 pm
	COFFEE BREAK	COFFEE BREAK	3.00 pm
			3.15 pm
COFFEE BREAK	LYMPHOMA WORKSHOP III	LYMPHOMA WORKSHOP VII	3.30 pm
			3.45 pm
DAVID MASON AWARD 2016			4.00 pm
DAVID MASON LECTURE			4.15 pm
		4.30pm-4.35pm CLOSING COMMENTS	4.30 pm
			4.45 pm
			5.15 pm
			5.30 pm
GENERAL ASSEMBLY			5.45 pm
			6.00 pm
			6.15 pm
			6.30 pm
			6.45 pm
			7.00 pm
			7.15 pm
			7.30 pm
			7.45 pm
NETWORKING DINNER			8.00 pm
			8.15 pm
			8.30 pm
			8.45 pm
			9.00 pm

1.00pm – 3.00pm <i>San Francisco</i>	THYMUS SYMPOSIUM Highlights of thymus pathology
Chairs	<i>Alexander Marx (Mannheim/Heidelberg, Germany)</i> <i>Philipp Ströbel (Göttingen, Germany)</i>
	Thymus Biology: the ins and outs of central tolerance <i>Sheena Pinto (Heidelberg, Germany)</i>
	Non-neoplastic thymic pathology <i>Alexandar Tzankov (Basel, Switzerland)</i>
	Neoplastic thymic pathology: the WHO classification and beyond <i>Alexander Marx (Mannheim/Heidelberg, Germany)</i>
	Novel insights into thymic cancer biology: the Cancer Genome Atlas project <i>Philipp Ströbel (Göttingen, Germany)</i>

3.00pm–3.15pm <i>San Francisco</i>	OPENING SESSION
---------------------------------------	------------------------

3.30pm–6.30pm <i>San Francisco</i>	EDUCATIONAL SESSION Updated WHO-classification of hematolymphoid neoplasms
Chairs	<i>Elias Campo (Barcelona, Spain)</i> <i>Steven H. Swerdlow (Pittsburgh, PA, USA)</i>
	Introduction <i>Steven H. Swerdlow (Pittsburgh, PA, USA)</i>
	Small B-cell lymphomas <i>Steven H. Swerdlow (Pittsburgh, PA, USA)</i>
	Aggressive B-cell lymphomas <i>Elias Campo (Barcelona, Spain)</i>

	COFFEE BREAK
	Peripheral T-cell lymphomas <i>Elaine S. Jaffe (Bethesda, MD, USA)</i>
	Acute leukemias and myelodysplastic syndromes <i>Dan Arber (San Francisco, CA, USA)</i>
	Myeloproliferative neoplasms <i>Attilio Orazi (New York, NJ, USA)</i>
7.30pm–9.00pm Exhibition Area – 2 nd Floor	WELCOME RECEPTION

7.15am–8.15am <i>Guangzhou</i>	MEET THE PROFESSOR
	Unusual manifestations of classical lymphoid entities <i>Marsha C. Kinney (San Antonio, TX, USA)</i>
7.15am–8.15am <i>Hong Kong</i>	MEET THE PROFESSOR
	Redefining the diagnostic boundaries of chronic myeloid neoplasms <i>Attilio Orazi (New York, NJ, USA)</i>
7.15am–8.15am <i>Mexico</i>	MEET THE PROFESSOR
	Lymphoma diagnosis: it is all about the clinical information-a love story of a pathologist and a telephone <i>Daphne de Jong (Amsterdam, NL)</i>
8.25am–8.30am <i>San Francisco</i>	Introduction Stephan Dirnhofer (Basel, Switzerland) Jon van der Walt (LONDON, UK)
8.30am–10.00am <i>San Francisco</i>	BONE MARROW SYMPOSIUM I
Chairs	<i>Ioannis Anagnostopoulos (Berlin, Germany)</i> <i>Emanuela Boveri (Pavia, Italy)</i>
	Histiocytes and the bone marrow. From phagocytosis to transdifferentiation <i>Robert Hasserjian (Boston, MA, USA)</i>

	<p>Plasmacytoid dendritic cell neoplasms <i>Fabio Facchetti (Brescia, Italy)</i></p>
	<p>Normal and leukemic stem cell niches: insights and therapeutic opportunities <i>Koen Schepers (Leiden, Netherlands)</i></p>
10.00am – 10.30am	COFFEE BREAK / POSTER VIEWING
10.30am – 11.30am <i>San Francisco</i>	<p>BONE MARROW SYMPOSIUM II Proffered papers</p>
Chairs	<p><i>Maurilio Ponzoni (Milano, Italy)</i> <i>Anna Porwit (Lund, Sweden)</i></p>
	<p>BMS-O-1 Recurrent point mutation in the mesenchymal stromal cells (MSC) of human acute myeloid leukemia (AML) <i>Emina Torlakovic (Toronto, Canada)</i></p>
	<p>BMS-O-2 Restoration of the nestin positive niche and decrease of myelofibrosis in bone marrow biopsies of patients with myeloproliferative neoplasms treated with mirabegron: preliminary report of the prospective phase II clinical trial SAKK 33/14 <i>Alexandar Tzankov (Basel, Switzerland)</i></p>
	<p>BMS-O-3 Characterization of the bone marrow micro-environment using NanoString nCounter analysis of formalin fixed paraffin embedded specimens from Myelofibrosis patients <i>N. Scott Reading (Salt Lake City, UT, USA)</i></p>
	<p>BMS-O-4 Myeloid neoplasms following solid organ transplantation: clinicopathologic studies of 22 cases <i>Endi Wang (Durham, NC, USA)</i></p>

11.30am–12.00pm <i>San Francisco</i>	BONE MARROW SYMPOSIUM II
Chairs	<i>Hans Kreipe (Hanover, Germany)</i> <i>Bogna Ziarkiewicz-Wróblewska (Warsaw, Poland)</i>
	TOPIC LECTURE Aggressive systemic mastocytosis <i>Dan Arber (Stanford, CA, USA)</i>
12.00pm–1.30pm	LUNCH BREAK / POSTER VIEWING
1.30pm–4.00pm <i>San Francisco</i>	BONE MARROW WORKSHOP / SESSION 1 & 2 Case presentations
16.00–16.30	COFFEE BREAK
4.30pm–6.00pm <i>San Francisco</i>	BONE MARROW WORKSHOP / SESSION 3 Case presentations and poster prize award
6.00pm–6.30pm <i>San Francisco</i>	EBMWG BUSINESS MEETING <i>Members only</i>

<p>7.15am–8.15am <i>Guangzhou</i></p>	<p>MEET THE PROFESSOR</p>
	<p>Redefining the diagnostic boundaries of chronic myeloid neoplasms <i>Attilio Orazi (New York, NY, USA)</i></p>
<p>7.15am–8.15am <i>Hong Kong</i></p>	<p>MEET THE PROFESSOR</p>
	<p>Lymphoma diagnosis: it is all about the clinical information-a love story of a pathologist and a telephone <i>Daphne de Jong (Amsterdam, NL)</i></p>
<p>7.15am–8.15am <i>Mexico</i></p>	<p>MEET THE PROFESSOR</p>
	<p>Hematopathologic diagnoses too easy to miss <i>Steven H. Swerdlow (Pittsburgh, PA, USA)</i></p>
<p>8.30am–9.00am <i>San Francisco</i></p>	<p>KEYNOTE LECTURE Genetic aspects of aggressive lymphomas <i>Riccardo Dalla-Favera (New York, NJ, USA)</i></p>
<p><i>Chair</i></p>	<p><i>Stephan Dirnhofer (Basel, Switzerland)</i></p>

9.00am – 10.00am <i>San Francisco</i>	LYMPHOMA SYMPOSIUM I Aggressive B-cell lymphoma
Chairs	<i>Stephan Dirnhofer (Basel, Switzerland)</i> <i>Andrew Wotherspoon (London, UK)</i>
	LYS-0-1-1 Role of smoothed in the pathobiology of diffuse large B-cell lymphoma <i>Francisco Vega (Miami, FL, USA)</i>
	LYS-0-1-2 Cell-of-Origin-Classification using the Lymph2Cx predictor in FFPE embedded samples of young poor-prognosis and elderly patients with diffuse large B-cell lymphoma <i>Heike Horn (Stuttgart, Germany)</i>
	LYS-0-1-3 Genetic and immunophenotypic characterization of diffuse large B-cell lymphoma in children and young adults <i>Itziar Salaverria (Barcelona, Spain)</i>
	LYS-0-1-4 Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome wide copy number aberration and targeted sequencing analysis <i>Darius Juskevicius (Basel, Switzerland)</i>
10.00am – 10.30am	COFFEE BREAK
10.30am – 11.00am <i>San Francisco</i>	KEYNOTE LECTURE Clinical aspects of aggressive lymphomas <i>Michele Ghielmini (Bellinzona, Switzerland)</i>
Chair	<i>Leticia Quintanilla-Fend (Tübingen, Germany)</i>

11.00am–12.00am <i>San Francisco</i>	LYMPHOMA SYMPOSIUM II Aggressive B-cell lymphoma
Chairs	<i>Stefania Pittaluga (Bethesda, MD, USA)</i> <i>Leticia Quintanilla-Fend (Tübingen, Germany)</i>
	LYS-0-2-1 Primary mediastinal large B-cell lymphoma (PMBL) arising in non-mediastinal sites <i>Stephanie Ellen Weissinger (Ulm, Germany)</i>
	LYS-0-2-2 Deciphering the genetic foundation of follicular lymphoma transformation to diffuse large B-cell lymphoma <i>Julia Gonzalez Rincon (Madrid, Spain)</i>
	LYS-0-2-3 Prospective assessment and prognostic significance of MYC and BCL2 expression and rearrangements in diffuse large B-cell lymphoma (DLBCL) – All Wales Lymphoma Panel study <i>Matthew Richard Pugh (Cardiff, UK)</i>
	LYS-0-2-4 MYC overexpression in plasmablastic lymphoma is related with recurrent mutations in PRDM1/Blimp1 <i>Santiago Montes-Moreno (Santander, Spain)</i>
12.00pm–1.30pm	LUNCH BREAK / POSTER VIEWING
2.30pm–3.00pm	COFFEE BREAK
3.00pm–3.30pm <i>San Francisco</i>	KEYNOTE LECTURE Epigenetic changes in germinal-center B-cell derived lymphomas <i>Reiner Siebert (Ulm, Germany)</i>
Chair	<i>Daphne de Jong (Amsterdam, NL)</i>

<p>3.30pm–4.00pm <i>San Francisco</i></p>	<p>LYMPHOMA SYMPOSIUM III The microenvironment in lymphomas</p>
<p>Chairs</p>	<p><i>Daphne de Jong (Amsterdam, NL)</i> <i>Yaso Natkunam (Stanford, CA, USA)</i></p>
	<p>LYS-0-3-1 Impaired functional responses despite productive TCR triggering in follicular lymphoma CD8+TIM-3+T lymphocytes <i>Camille Laurent (Toulouse, France)</i></p>
	<p>LYS-0-3-2 Integrated microenvironment and genomic analysis to identify poor prognosis follicular lymphoma patients: a study from the Lunenburg Lymphoma Biomarker consortium <i>Wendy Stevens (Nijmegen, NL)</i></p>
<p>4.00pm–5.00pm <i>San Francisco</i></p>	<p>KARL LENNERT LECTURE Back to Basel <i>Philip Kluin (Groningen, NL)</i></p>
<p>Chair</p>	<p><i>Andrew Wotherspoon (London, UK)</i></p>

7.15am–8.15am <i>Guangzhou</i>	MEET THE PROFESSOR
	Unusual manifestations of classical lymphoid entities <i>Marsha C. Kinney (San Antonio, TX, USA)</i>
7.15am–8.15am <i>Hong Kong</i>	MEET THE PROFESSOR
	Hematopathologic diagnoses too easy to miss <i>Steven H. Swerdlow (Pittsburgh, PA, USA)</i>
7.15am–8.15am <i>Mexico</i>	MEET THE PROFESSOR
	The differential diagnosis of myelodysplastic syndromes <i>Robert Hasserjian (Boston, MA, USA)</i>
8.30am–9.00am <i>San Francisco</i>	KEYNOTE LECTURE Molecular pathogenesis of germinal center-derived B cell lymphomas <i>Ralf Küppers (Essen, Germany)</i>
<i>Chair</i>	<i>Wolfram Klapper (Kiel, Germany)</i>
9.00am–10.00am <i>San Francisco</i>	LYMPHOMA SYMPOSIUM IV Indolent lymphomas
<i>Chairs</i>	<i>Esther Garamvölgyi (Marly, Switzerland)</i> <i>Wolfram Klapper (Kiel, Germany)</i>
	Topic Lecture Indolent lymphomas with morphological or molecular features of aggressiveness <i>James Cook (Cleveland, USA)</i>

	<p>LYS-0-4-1 Pediatric type and t(14;18)-negative follicular lymphoma are genetically different diseases <i>Janine Schmidt (Tübingen, Germany)</i></p>
	<p>LYS-0-4-2 Activation of oncogene enhancers by Notch signaling in small B-cell lymphomas <i>Rusell Ryan (Boston, USA)</i></p>
10.00am – 10.30am	COFFEE BREAK
10.30am – 11.45am	POSTER SESSION
Chairs	<p><i>John Goodlad (Leeds, UK)</i> <i>Sergio Cogliatti (St. Gallen, Switzerland)</i> <i>Alberto Zamò (Verona, Italy)</i></p>
11.45am – 12.45pm <i>San Francisco</i>	<p>LYMPHOMA SYMPOSIUM V Aggressive B-cell lymphoma</p>
Chairs	<p><i>Maria Calaminici (London, UK)</i> <i>Philippe Gaulard (Paris, France)</i></p>
	<p>Topic Lecture Aggressive B-cell lymphomas <i>German Ott (Stuttgart, Germany)</i></p>
	<p>LYS-0-5-1 The pathogenesis of endemic Burkitt lymphoma <i>Dennis Wright (Southampton, UK)</i></p>

	<p>LYS-0-5-2 Does MYC protein expression correlate with MYC gene translocation in Burkitt Lymphoma? A possible role of N-MYC <i>Lorenzo Leoncini (Siena, Italy)</i></p>
--	--

12.45pm–3.00pm	LUNCH BREAK
----------------	-------------

2.30pm–3.30pm <i>San Francisco</i>	<p>LYMPHOMA SYMPOSIUM VI Accessory cells and histiocytic neoplasms</p>
---------------------------------------	--

Chairs	<p><i>Eugenia Haralambieva (Zuerich, Switzerland)</i> <i>Birgitta Sander (Stockholm, Sweden)</i></p>
--------	---

	<p>Topic Lecture Accessory and histiocytic neoplasms – from benign to malignant <i>Fabio Facchetti (Brescia, Italy)</i></p>
--	--

	<p>LYS-0-6-1 Next generation sequencing unravels the causes of aggressive behavior and B-cell transdifferentiation in Langerhans cell proliferation <i>Luc Xerri (Marseille, France)</i></p>
--	--

	<p>LYS-0-6-2 Identification of novel follicular dendritic cell sarcoma markers by whole transcriptome sequencing <i>Luisa Lorenzi (Brescia, Italy)</i></p>
--	--

3.30pm–4.00pm	COFFEE BREAK
---------------	--------------

<p>4.00pm–4.30pm <i>San Francisco</i></p>	<p>DAVID MASON AWARD 2015 / 2016 Recurrent mutations in genes involved in nuclear factor kappa B signaling in nodal marginal zone lymphoma <i>Michiel van den Brand (Nijmegen, Netherlands)</i></p>
<p>4.30pm–5.30pm <i>San Francisco</i></p>	<p>DAVID MASON LECTURE The molecular pathogenesis of myeloproliferative neoplasms <i>Radek Skoda (Basel, Switzerland)</i></p>
<p>Chairs</p>	<p><i>Teresa Marafioti (London, UK)</i> <i>Andrew Wotherspoon (London, UK)</i></p>
<p>5.30pm–7.00pm <i>San Francisco</i></p>	<p>GENERAL ASSEMBLY <i>Members only</i></p>
<p>8.00pm–11.00pm</p>	<p>NETWORKING DINNER Markthalle Basel (<i>further details, please refer to page 50</i>) <i>Tickets required</i></p>

<p>8.30am – 10.30am <i>Montreal</i></p>	<p>LYMPHOMA SYMPOSIUM VII Recent advances</p>
<p>Chairs</p>	<p><i>Marja-Liisa Karjalainen-Lindsberg (Helsinki, Finland)</i> <i>Megan Lim (Philadelphia, PA, USA)</i></p>
	<p>Topic Lecture The potential of new diagnostic methods in hematolymphoid neoplasms <i>Richard Rosenquist (Uppsala, Sweden)</i></p>
	<p>LYS-0-7-1 Exploring the genetic landscape of post-transplant lymphoproliferative disorders <i>Thomas Menter (London, UK)</i></p>
	<p>LYS-0-7-2 Recurrent STAT6 and GNA13 mutations in classical Hodgkin lymphoma <i>Enrico Tiacci (Perugia, Italy)</i></p>
	<p>LYS-0-7-3 Plasma vesicle-associated miRNAs are response markers for primary and relapsed Hodgkin lymphoma patients <i>Kimberly van der Oord (Amsterdam, NL)</i></p>
	<p>LYS-0-7-4 miR-125b and miR-150 are key players in ALK-positive ALCL <i>Pierre Brousset (Toulouse, France)</i></p>
	<p>LYS-0-7-5 De novo gene mutations in human IgG memory B-cells with hypermutated immunoglobulin genes <i>Carel Van Noesel (Amsterdam, NL)</i></p>

	LYS-0-7-6 Detection of rearranged light chain sequences by RNA-Seq in B-cell lymphomas and reactive lymphadenopathies <i>Alberto Zamo (Verona, Italy)</i>
10.30am – 11.00am	COFFEE BREAK
11.00am – 12.30pm <i>Montreal</i>	LYMPHOMA WORKSHOP Accessory cells & histiocytic neoplasms
12.30pm – 3.30pm	LUNCH BREAK
1.30pm – 3.00pm <i>Montreal</i>	LYMPHOMA WORKSHOP Accessory cells & histiocytic neoplasms
3.00pm – 3.30pm	COFFEE BREAK
3.30pm – 5.30pm <i>Montreal</i>	LYMPHOMA WORKSHOP Burkitt lymphoma with atypical features

8.00am – 10.00am <i>Montreal</i>	LYMPHOMA WORKSHOP Indolent B-cell lymphomas with aggressive features
10.00am – 10.30am	COFFEE BREAK
10.30am – 12.30pm <i>Montreal</i>	LYMPHOMA WORKSHOP De novo large B-cell lymphomas with morphological features suggesting more aggressive behavior
12.30pm – 1.30pm	LUNCH BREAK
1.30pm – 3.00pm <i>Montreal</i>	LYMPHOMA WORKSHOP De novo large B-cell lymphomas with morphological features suggesting more aggressive behavior
3.00pm – 3.30pm	COFFEE BREAK
3.30pm – 4.30pm <i>Montreal</i>	LYMPHOMA WORKSHOP Large B-cell lymphomas with unexpected indolent behavior
4.30pm – 4.35pm <i>Montreal</i>	CLOSING CEREMONY

Poster Presentations

Poster Presentation

Posters will be exhibited in the Poster Exhibition Area on the 2nd floor. They are aimed to give a crisp overview on current research activities and to initiate discussions.

All conference participants are invited to join.

Poster viewing:

- Sunday, September 4, 2016 from 10.00am – 10.30am and 12.00pm – 1.30pm
- Monday, September 5, 2016 from 12.00pm – 1.30pm

The official lymphoma poster session:

- Tuesday, September 6, 2016 from 10.30am – 11.45am

A prize for the best Bone Marrow Symposium poster will be awarded at the close of the Bone Marrow Workshop.

POSTER PRESENTATION – BONE MARROW SYMPOSIUM

BMS-P-1

Child with both Langerhans Cell Histiocytosis and Juvenile Xanthogranuloma Diseases - case report

J. B. Castelli^{1,2}, E. R. Biojone³, M. C. N. Zerbini⁴, M. D. L. F. Chauffaille⁵

¹Pathology, Fleury - Medicina e Saúde, ²Pathology, InCor-Hospital das Clínicas-FMUSP, São Paulo, ³Oncopediatrics, Hospital da Criança de Brasília José Alencar, Brasília, ⁴Pathology, Faculdade de Medicina da USP, ⁵Cytogenetics, Fleury - Medicina e Saúde, São Paulo, Brazil

BMS-P-2

An unusual case of CLL evolving to Langerhans Cell Histiocytosis with acquisition of mutations in BRAF and STK11

B. Federmann¹, I. Bonzheim¹, S. Wirths², J. Steinhilber¹, W. Bethge², F. Fend¹

¹Institute for Pathology and Neuropathology, ²Medical Department, Hematology and Oncology, Comprehensive Cancer Center and University Hospital Tuebingen, Tübingen, Germany

BMS-P-3

The MAPK/ERK pathway activation in patients with Langerhans Cell Histiocytosis

O. Novosad¹, I. Kryachok¹, N. Khranovska², N. Svergun², O. Skachkova²

¹Oncohematology, ²Experimental Oncology, National Cancer Institute, Kiev, Ukraine

Poster Presentations

BMS-P-4

Langerin negative Langerhans cell sarcoma: an electronmicroscopic diagnosis

Y. L. Hock¹, E. M. Curtis², B. Vydyanath²

¹Histopathology, Walsall Healthcare NHS Trust, Walsall, ²Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

BMS-P-5

Cytokine profile, therapy response in secondary idiopathic Haemophagocytic lymphohistiocytosis

S. K. Nagumantry¹, S. Beck²

¹Haematology, Peterborough City Hospital, Addenbrookes Hospital, ²Immunology, Peterborough City Hospital, Peterborough, United Kingdom

BMS-P-6

The distinct transcriptional profile (TP) of follicular dendritic cell sarcoma (FDCS) provides insights into its histogenesis and microenvironment.

M. A. Laginestra¹, C. Tripodo², C. Agostinelli¹, G. Motta¹, F. Melle¹, M. Rossi¹, C. Döering³, S. Hartmann³, M. R. Sapienza¹, F. Fuligni⁴, G. Anna¹, C. Mannu¹, S. Carlo¹, L. Lorenzi⁵, F. Bacci¹, E. Sabbatini¹, M.-L. Hansmann³, F. Facchetti⁵, S. A. Pileri⁶

¹Bologna University, Bologna, ²Palermo University, Palermo, Italy, ³Frankfurt University, Frankfurt, ⁴Toronto University, Toronto, ⁵Brescia University, Brescia, ⁶IEO, Milan, Italy

BMS-P-7

Mast cell sarcoma: a rare tumor with a poor prognosis

D. Canioni^{1,2}, J. Bruneau^{1,2}, S. Georjin-Lavialle^{2,3}, J. Monnier³, M.-O. Chandesris^{2,4}, L. Lhermitte^{2,5}, T. Molina¹, G. Damaj^{2,6}, O. Hermine^{2,4}

¹Pathology Department, ²Centre de Référence des Mastocytoses, Hopital Necker, ³Internal Medicine, Hopital Tenon, ⁴Hematology, ⁵Hematology Biology, Hopital Necker, PARIS, ⁶Hematology Insitute of Basse Normandie, Centre Hospitalier Universitaire, Caen, France

BMS-P-8

ALK positive histiocytic sarcoma

S. Ota¹, T. Shimoi², K. Takeuchi³, N. Nakamura⁴, E. Sakaida⁵, C. Ohwada⁵, C. Nakaseko⁵, K. Yonemori², K. Tamura², Y. Nakatani¹

¹Pathology, Chiba University Hostpital, Chiba, ²Breast and Med. Oncol., Natl. Cancer Ctr. Hosp, ³Pathology, Pathology Project for Molecular Targets and Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, ⁴Tokai University, Tokyo, ⁵Hematology, Chiba University Hostpital, Chiba, Japan

Poster Presentations

BMS-P-9

Extranodal Rosai Dorfman Disease – is it a different entity?

A. Verma¹, T. Shet¹, S. Epari¹, S. Gujral¹, M. Sengar², B. Aurora³, H. Menon² and Adult and Pediatric Disease Management Group, Tata Memorial Hospital

¹Dept Of Pathology, ²Adult hematology DMG, ³Pediatric Hematology DMG, Tata Memorial Hospital, Mumbai, India

BMS-P-10

A case report of Myeloid sarcoma presenting as bile duct and vaginal submucosal tumor

M. Shimura¹, S. Ota², W. Masuda³, Y. Isshiki⁴, C. Ohwada⁴, E. Sakaida⁴, C. Nakaseko⁴, Y. Nakatani²

¹School of Medicine, Chiba University, ²Pathology, Chiba Univ. Hosp., ³Molecular and Tumor Pathology, Chiba Univ. Grad. Sch. Med., ⁴Hematology, Chiba Univ. Hosp., Chiba, Japan

BMS-P-11

Aggressive systemic mastocytosis: a case series from a large UK referral centre

A. Green¹, L. Raso-Barnett¹, C. Harrison², J. van der Walt¹, D. Radia², M. Moonim¹

¹Histopathology, ²Haematology, Guys and St Thomas Hospital, London, United Kingdom

BMS-P-12

A de novo mast cell leukemia without KIT D816V mutation or myelomastocytic leukemia with c-kit over-expression? A case report

G. Balatzenko¹, B. Hrishev², B. Spassov², M. Guenova³

¹Laboratory of Cytogenetics and Molecular Biology, ²Haematology Clinic, ³Laboratory of Hematopathology and Immunology, National Specialised Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria

BMS-P-13

Blastic plasmacytoid dendritic cell neoplasm: a single center experience of 13 patients documenting frequent CNS involvement and CD33 positivity

J. Ferreira¹, A. Robson, J. Costa-Rosa, J. Cabecadas

Pathology, IPO Lisboa FG, Lisboa, Portugal

Poster Presentations

BMS-P-14

Clinical and pathologic characteristics of blastic plasmacytoid dendritic cell neoplasms – a single center experience

Y. Georgieva¹, T. Dikov¹, K. Prisdashka², A. Michova³, B. Spassov⁴, G. Balatzenko⁵, M. Guenova¹

¹Laboratory of Hematopathology and Immunology, National Specialised Hospital for Active Treatment of Hematological Diseases, ²Dermatology Clinic, ³Laboratory of Hematopathology and Immunology, University Hospital Alexandrovska, ⁴Haematology Clinic, ⁵Laboratory of Cytogenetics and Molecular Biology, National Specialised Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria

BMS-P-15

A nationwide multicenter project to promote diagnosis of Gaucher disease by applying an algorithm within high risk patients with splenomegaly and/or thrombocytopenia

V. Madzharova¹, V. Hrishev¹, G. Georgiev², S. Spassova³, I. Galabova², T. Alaykov³, V. Grklanov⁴, E. Spassov⁴, K. Marinova⁵, D. Kostov⁶, S. Panayotova⁷, A. Stoyanova⁴, I. Sinigerska⁸, M. Guenova¹, E. Hadjiev⁹

¹Natl Hematology Hosp, ²Tokuda Hospital, ³Sofiamed, Sofia, ⁴University Hospital Sv. Georgi, Plovdiv, ⁵MBAL Ruse, Ruse, ⁶DKC1, Burgas, ⁷University Hospital Georgi Stranski, Pleven, ⁸National Genetic Laboratory, ⁹Aleksandrovska Hospital, Sofia, Bulgaria

BMS-P-16

Different osteopontin variants are involved in the maintenance of the bone marrow niche in an in vitro niche model

D. Confalonieri¹, F. Ehlicke², H. Walles¹

¹Translational Center Würzburg Regenerative Therapies in Oncology and Musculoskeletal Disease; Fraunhofer IGB, ²Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Würzburg, Germany

BMS-P-17

Connective tissue growth factor immuno-staining expression pattern in bone marrow elements in various disease states

S. H. Rizk¹, S. H. Kandil², M. A. Zidan³, H. El-Hosseiny¹, K. Momen², A. Foad⁴, A. N. E.-D. Sherif⁵

¹Clinical pathology, Cairo University, ²Clinical pathology, Monofya University, ³Clinical pathology, Banha University, Cairo, ⁴Clinical pathology, Monofya University, Monofya, ⁵Clinical pathology, Banha University, Banha, Egypt

Poster Presentations

BMS-P-18

Functional regulation of von Willebrand factor by ADAMTS13 improves microcirculation of the marrow for the better cell engraftment efficacy in mouse model of bone marrow transplantation

M. Sugimoto^{*}, H. Matsui

Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Japan

BMS-P-19

Therapy-related acute myeloid leukaemia presenting simultaneously with breast cancer metastasis: report of a case

V. Cemerikic Martinovic^{*} 1, S. Sretenovic², S. Mitrovic³, P. Djurdjevic²

¹Pathology, Beo-lab, Belgrade, ²Hematology Clinic, ³Pathology, Clinical Centre Kragujevac, Kragujevac, Serbia

BMS-P-20

Clonal cytogenetic abnormalities in “normal” bone marrow status post treatment for B-lymphoblastic leukemia: therapy-induced regression to occult myelodysplastic neoplasm and sign of genomic instability associated with relapse as distinct phenotype

B. Wu^{1,2}, J. Galeotti¹, C. Rehder¹, A. Lagoo¹, E. Wang^{*} 1

¹Duke University Medical Center, Durham, United States, ²Hematology, Shengjing Hospital, Shenyang, China

BMS-P-21

Prevalence of the JAK2 V617F mutation in Srinagarind hospital Khon Kaen, Thailand between June 2013 - June 2014

K. Chaicom^{*} 1, C. Sirijerachai¹, K. Chansung¹, B. Palaeng¹, P. Klangsang¹, P. Chaimanee², P. Anangta²

¹Department of Medicine, Medicine Faculty, KhonKaen University, KhonKaen University, ²Central Laboratory Srinagarind Hospital, Srinakarind Hospital Khon Kaen University, Khon Kaen, Thailand

BMS-P-22

Extreme Hyperferritinemia associated with secondary Macrophage Activation Syndrome (MAS) in a patient with HIV and tuberculosis

M. Kurdi^{*}

Clinical laboratory, Simone Veil Hospital, Eaubonne, France

Poster Presentations

BMS-P-23

Distribution of NPM1 and FLT3 mutations in AML patients

A. Toylu¹, B. Akkaya^{*2}, O. Salim³, S. Karauzum¹, L. Undar³

¹Medical Genetics, ²Pathology Dept., ³Hematology, Akdeniz University School of Medicine, Antalya, Turkey

BMS-P-24

Next-generation sequencing for T-cell receptor gamma gene rearrangements enables accurate and specific identification of T-cell clones in clinical hematologic specimens

R. Kansal^{*1,2}, W. W. Grody¹, J. Said¹, J. Zhou¹, L. Dong¹, J. E. Miller³, M. Klass³, X. Li¹

¹Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles,

²Pathology and Laboratory Medicine, Penn State Hershey Medical Center/Penn State College of Medicine (current), Hershey, ³Invivoscribe Technologies, Inc., San Diego, United States

BMS-P-25

Plasma cell leukemia: a series of eight cases

A. Ranjan^{*}, R. Pramanik, P. Tanwar

Lab Oncology, Medical Oncology, Aiiims, New Delhi, New Delhi, India

BMS-P-26

Plasmablastic myeloma presenting as plasmablastic lymphoma

A. Ranjan^{*}, R. Pramanik, P. Tanwar

Lab Oncology, Medical Oncology, Aiiims, New Delhi, New Delhi, India

Poster Presentations

POSTER PRESENTATION – LYMPHOMA SYMPOSIA

LYS-P-1

Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma

S. Hartmann¹, B. Schuhmacher¹, T. Rausch², L. Fuller¹, C. Döring¹, M. Weniger³, A. Lollies³, C. Weiser¹, L. Thurner⁴, B. Rengstl¹, U. Brunnberg⁵, M. Vornanen⁶, M. Pfreundschuh⁷, V. Benes⁸, R. Küppers⁹, S. Newrzela¹⁰, M.-L. Hansmann¹⁰

¹Pathology, Goethe Universität, Frankfurt, ²Genecore, EMBL, Heidelberg, ³Institute of cell biology, Essen University, Essen, Germany, ⁴José Carreras Center for Immuno- and Gene Therapy, Saarland University Medical School, Homburg, -, ⁵Internal Medicine 2, Goethe Universität, Frankfurt, Germany, ⁶Pathology, Fimlab, Tampere, Finland, ⁷Saarland University Medical School, Homburg, ⁸EMBL, Heidelberg, ⁹Essen University, Essen, ¹⁰Goethe Universität, Frankfurt, Germany

LYS-P-2

Intralymphatic spread in extranodal diffuse large-B cell lymphoma: a rare finding associated with poor prognosis

S.-C. Yu¹, C.-L. Cheng², C.-W. Lin¹, M.-S. Hsieh¹, H.-C. Lien¹, C.-C. Wang¹, P.-H. Huang¹, S.-C. Chou², S.-H. Kuo³, M. Yao², J.-H. Liu⁴, Y.-S. Lu³, H.-K. Liang³, Y.-Y. Shao³

¹Department of Pathology, ²Department of Internal Medicine, ³Department of Oncology, ⁴Tai-Cheng Stem Cell Therapy Center, National Taiwan University Hospital, Taipei, Taiwan

LYS-P-3

The T-lineage transcription factors GATA-3 and LEF-1 are expressed in classical Hodgkin lymphoma (CHL) and are associated with loss of B-lineage identity

A. Ruano¹, C. Cotta

Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, United States

LYS-P-4

Challenges in Pediatric Primary bone diffuse large B-cell lymphoma

S. El Hussein¹, C. Brathwaite², L. Pelaez², A. Catellano-Sanchez¹

¹Pathology and laboratory medicine, Mount Sinai Medical Center, Miami Beach, ²Pathology and laboratory medicine, Nicklaus children's hospital, Miami, United States

LYS-P-5

Correlation of immunohistochemistry and proliferation rate/aggressive behavior in diffuse large B-cell lymphoma

X. Zhang¹, K. Zhang²

¹Geisinger Health System, Wilkes-Barre, ²Geisinger Health System, Danville, United States

Poster Presentations

LYS-P-6

Targeted mutational analysis of a diffuse large B-cell lymphoma clinical trial cohort identifies CREBBP mutations as an independent prognostic factor

D. Juskevicius¹, D. Jucker, S. Dirnhofer, A. Tzankov

Institute of Pathology, University Hospital Basel, Basel, Switzerland

LYS-P-7

Anaplastic variant of diffuse large B-cell lymphoma: a distinct tumor with high frequency of TP53 mutations and concurrent MYC and BCL2/BCL6 abnormalities

Z. Wang¹, M. Li, Y. Liu, Y. Wang, Q. Yan, Y. Guo, S. Guo

Department of Pathology, Xi Jing Hospital, the Fourth Military Medical University, Xi'an, China

LYS-P-8

Experience of two center's histopathological and immunohistochemical characteristics of Hodgkin's lymphomas from in Mediterranean Turkey

B. Akkaya¹, H. Akkaya², O. Salim³, K. Yalcin⁴, E. Guler⁴

¹Pathology Department, Akdeniz University School of Medicine, Antalya, ²Pathology Department, Baskent University Faculty of Medicine, Ankara, ³Hematology Dep, ⁴Pediatric Hematology-Oncology Dep., Akdeniz University School of Medicine, Antalya, Turkey

LYS-P-9

An unusual case of Burkitt's lymphoma presenting as a gingival enlargement

B. Akkaya¹, I. H. Ozbudak¹, A. B. Toptas²

¹Pathology Department, ²Otolaryngology-Head and Neck Surgery Department, Akdeniz University School of Medicine, Antalya, Turkey

LYS-P-10

Th17 differentiation and loss of plasticity after mutational SOCS1 inactivation in a T-cell lymphoma with an activating JAK3 mutation

R. A. F. MacLeod¹, S. Ehrentraut¹, B. Schneider², S. Nagel¹, C. Pommerenke¹, H. Quentmeier¹, R. Geffers³, M. Feist⁴, M. Kaufmann¹, C. Meyer¹, M. E. Kadin⁵, H. G. Drexler¹

¹Leibniz Institute - DSMZ, German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures, Braunschweig, Germany, ²University of Rostock, Institute of Pathology and Molecular Pathology, Rostock, Germany, ³HZI - Helmholtz Center for Infection Research, Genome Analytics Research Group, Braunschweig, Germany, ⁴University Medical Center Goettingen, Department of Haematology and Medical Oncology, Goettingen, Germany, ⁵Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Boston University School of Medicine, Providence, RI, USA

Poster Presentations

LYS-P-11

CD30 expression in adult primary central nervous system diffuse large B-cell lymphoma

H. S. Abd El All^{1,2}

¹Pathology, Suez Canal University, Faculty of Medicine, Ismailia, ²Immunohistochemistry Lab, Nasser Institute, Cairo, Egypt

LYS-P-12

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project

A. Perry^{*1}, J. Diebold², B. Nathwani³, K. MacLennan⁴, H. K. Müller-Hermelink⁵, M. Bast⁶, E. Boilesen⁷, J. Armitage⁸, D. Weisenburger⁹

¹Department of Pathology, University of Manitoba, Winnipeg, Canada, ²Department of Pathology, Hotel-Dieu, University Denis Diderot, Paris, France, ³City of Hope National Medical Center, Duarte, United States, ⁴Section of Pathology and Leeds Institute of Molecular Medicine, St. James University Hospital, Leeds, United Kingdom, ⁵Institute of Pathology, University of Würzburg, Würzburg, Germany, ⁶Department of Internal Medicine, University of Nebraska Medical Center, ⁷Center for Collaboration on Research Design and Analysis, ⁸Department of Internal Medicine, University of Nebraska Medical Center, ⁹Department of Pathology, City of Hope National Medical Center, Omaha, United States

LYS-P-14

15 cases of Double Hit Lymphoma (DHL) and atypical DHL (aDHL): clinical and pathologic features and outcomes

K. Zhang^{*}, M. X. Zhang

Medical Laboratory, Geisinger Health System, Danville, United States

LYS-P-15

Toll-like receptor expression and function differ between splenic marginal zone B-cell lymphoma and splenic diffuse red pulp B-cell lymphoma

A. Verney¹, A. Traverse-Glehen², L. Genestier¹, E. Callet-Bauchu², L. Jallades², J. P. Magaud², G. Salles², L. Baseggio^{*2}

¹UMR5239, ²Hospices Civils de LYON, Pierre Benite, France

LYS-P-16

Non-mediastinal gray zone lymphoma and its microenvironment

T. Koletsa^{*}, A. Iliadis, V. Tzioufa, I. Kostopoulos

¹Pathology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Poster Presentations

LYS-P-17

Most primary effusion lymphomas in Taiwan are large B-cell lymphomas of non-GCB phenotype unrelated to HHV8

B.-J. Chen¹, S.-S. Chuang²

¹Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei City, ²Pathology, Chi-Mei Medical Center, Tainan, Taiwan

LYS-P-18

Aggressive B-cell lymphomas: a three year study from a tertiary cancer centre in South India

R. A. Nair¹, J. A. Vasudevan¹, P. M. Jacob¹, R. Sukumaran¹, S. Nair²

¹Pathology, ²Medical oncology, Regional Cancer Centre Trivandrum, Trivandrum, India

LYS-P-19

Tumor microenvironment and cytokines serve as prognostic marker in differential phenotypes of diffuse large B-cell lymphoma

V. Aggarwal¹, R. Srinivasan², A. Bal¹, P. Malhorta³, G. Prakash³, S. Varma³, A. Das¹

¹Department of Histopathology, ²Department of Cytology and Gynaecological Pathology, ³Department of Internal Medicine and Hemato-oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

LYS-P-20

Clinical implications of gastric mucosa-associated lymphoid tissue lymphomas with distinct plasmacytic differentiation

S. Park^{*}

Pathology, Ewha Womans University, Seoul, Republic of Korea

Poster Presentations

LYS-P-21

BCL2 break positive and negative follicular lymphomas show similarities and differences in their SNV profiles

A. Zamo¹, J. Pischmarov², M. Schlesner³, P. Rosenstiel⁴, C. López⁵, A. Haake⁵, J. Richter⁶, T. Grieb², T. Nedeva², L. Trümper⁷, C. Lawrenz⁸, W. Klapper⁶, P. Möller⁹, M. Hummel¹⁰, D. Lenze¹⁰, M. Szczepanowski¹¹, M. Schreder¹², L. Flossbach², H. Horn¹³, G. Ott¹⁴, R. Siebert⁵, A. Rosenwald², E. Leich²

¹Diagnostic and Public Health, University of Verona, Verona, Italy, ²Pathologie, Universität Würzburg, Würzburg, ³Theoretical Bioinformatics (B080) Computational Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, ⁴Institut für Klinische Molekularbiologie, Christian-Albrechts-Universität, Kiel, ⁵Institut für Humangenetik, ⁶Sektion Hämatopathologie und LKR, Universitätsklinikums Schleswig-Holstein, Kiel, ⁷Klinik für Hämatologie und Medizinische Onkologie, Universitätsmedizin Göttingen, Göttingen, ⁸Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, ⁹Pathologie, Universitätsklinikum Ulm, Ulm, ¹⁰Pathologie, Charité - Universitätsmedizin Berlin, Berlin, ¹¹Medizinische Klinik, Universitätsklinikums Schleswig-Holstein, Kiel, ¹²Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, ¹³Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, ¹⁴Institut für Klinische Pathologie, Robert-Bosch-Krankenhaus, Stuttgart, Germany

LYS-P-22

Integration of transcript expression, copy number and LOH analysis of PD1-positive nodal peripheral T-cell lymphoma

Q. Yang^{*}, E. Leich, A. Rosenwald, A. Zamo, T. Nedeva, H.-K. Müller-Hermelink
Pathologisches Institut der Universität Würzburg, Würzburg, Germany

LYS-P-23

Mutational analysis of pediatric Langerhans cell histiocytosis: correlation with long-term clinical follow-up

D. Nann¹, P. Schneckenburger², J. Steinhilber¹, G. Metzler³, R. Beschoner⁴, C. P. Schwarze², P. Lang², R. Handgretinger², F. Fend¹, M. Ebinger², I. Bonzheim¹

¹Department of Pathology and Neuropathology, Institute of Pathology, ²Children's Hospital, Department I – General Pediatrics, Hematology and Oncology, ³Department of Dermatology, ⁴Department of Pathology and Neuropathology, Institute of Neuropathology, University Hospital Tübingen, Tübingen, Germany

LYS-P-24

Targeted next generation sequencing in gastric marginal zone lymphoma reveals a distinct mutation signature

M. Rudelius^{*}, L. Flossbach, A. Rosenwald
Pathology, University of Wuerzburg, Wuerzburg, Germany

Poster Presentations

LYS-P-25

Primary gastric follicular lymphoma: report of 3 Korean cases and review of the literature

J. E. Kim¹, H. Y. Na², Y. A. Kim¹, S. K. Min³, C. Lee², S. Jung-Weon⁴, G. Park⁵, S. J. Choi⁶, H. K. Kim⁷, H.-J. Kim⁸, J. H. Han⁹

¹Pathology, Seoul National University Boramae Hospital, ²Pathology, Seoul National University Hospital, Seoul, ³Pathology, Hallym University Sacred Heart Hospital, Anyang, ⁴Pathology, Dongtan Sacred Heart Hospital Hallym University, ⁵Pathology, Seoul St. Mary's Hospital, The Catholic University, Seoul, ⁶Pathology, Inha University Hospital, Incheon, ⁷Pathology, Soonchunhyang University Hospital, Bucheon, ⁸Pathology, Inje University Sanggye Paik Hospital, Seoul, ⁹Pathology, Ajou University School of Medicine, Suwon, Republic of Korea,

LYS-P-26

De novo diffuse large B-cell lymphoma with TdT expression: report of 2 cases and review of the literature

L. Mendes^{*}, A. Wotherspoon

Histopathology, Royal Marsden Hospital, London, United Kingdom

LYS-P-27

Diffuse large B-cell lymphoma: "Abdominal type"

M. Abdulla^{*}, S. Laszlo, J. Triumpf, G. Hedström, M. Berglund, G. Enblad, R.-M. Amini

¹Dept of Immunology, Genetic and Pathology, Uppsala University, Uppsala, Sweden

LYS-P-28

Chlamydia psittaci infection is not associated with the ocular MALT lymphoma

U. Cho^{*}¹, J. E. Kim², H. J. Kim³, H. K. Kim⁴, S. K. Min⁵, G. Park¹, S. J. Choi⁶, J. H. Han⁷

¹Department of Pathology, College of Medicine, The Catholic University of Korea, ²Department of Pathology, Seoul National University Boramae Hospital, ³Department of Pathology, Inje University, Sanggye Paik Hospital, Seoul, ⁴Department of Pathology, Soonchunhyang University Hospital, Bucheon, ⁵Department of Pathology, Hallym University Sacred Heart Hospital, Anyang, ⁶Department of Pathology, Inha University Hospital, Incheon, ⁷Department of Pathology, Ajou University School of Medicine, Suwon, Korea, Republic Of

LYS-P-29

Reduced lymphotoxin-β production is associated with defective follicular dendritic cell (FDC) differentiation in follicular lymphoma (FL)

G. Pepe^{*}, A. di Napoli, S. Scarpino, C. Cippitelli, L. Ruco

Clinical and Molecular Medicine, Ospedale Sant'andrea, Roma, Italy

Poster Presentations

LYS-P-30

The prognostic significance of MUM1 positive tumour cell expression in follicular lymphoma: a single centre experience

M. Perunic Jovanovic¹, J. Jelacic², M. Todorovic^{2,3}, B. Andjelic^{2,3}, D. Antic^{2,3}, J. Bila^{2,3}, B. Mihaljevic^{2,3}

¹Department for pathology, ²Clinic of Haematology, Clinical Centre of Serbia, ³Faculty of Medicine, University of Belgrade, Belgrade, Serbia

LYS-P-31

EEF1G is a new partner of ALK in anaplastic large cell Lymphoma inducing constitutive ALK tyrosine kinase activation

G. Palacios¹, T. Shaw², Y. Li², R. Singh³, M. Valentine⁴, J. Sandlund⁵, M. Lim⁶, C. Mullighan¹, V. Leventaki¹

¹Pathology, ²Computational Biology, St. Jude Children's Research Hospital, Memphis, ³Pathology, Baylor College of Medicine, Houston, ⁴Cytogenetics, ⁵Oncology, St. Jude Children's Research Hospital, Memphis, ⁶Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States

LYS-P-32

Recurrent mutations in genes involved in nuclear factor kappa B signaling in nodal marginal zone lymphoma

M. van den Brand¹, J. Rijntjes¹, K. M. Hebeda¹, W. B. Stevens², W. J. van der Velden², B. B. Tops¹, J. H. J. van Krieken¹, P. J. Groenen¹

¹Pathology, ²Hematology, Radboud University Medical Center, Nijmegen, Netherlands

LYS-P-33

Genetic profiling of Hodgkin- and Reed-Sternberg cells (HRSC) of classical Hodgkin lymphoma (cHL) enriched from archival formalin-fixed and paraffin-embedded tissue samples

D. Juskevicius¹, D. Jucker, T. Dietsche, V. Perrina, C. Ruiz, S. Dirnhofer, A. Tzankov

Institute of Pathology, University Hospital Basel, Basel, Switzerland

LYS-P-34

Body cavity fluid flowcytometry in the diagnosis of haematolymphoid neoplasms

P. M. Jacob¹, R. A. Nair¹, J. A. Vasudevan¹, S. M. Koshy², S. Prem³, N. Nayak¹, R. Sukumaran¹, A. S¹

¹Pathology, ²Imageology, ³Medical Oncology, Regional Cancer Centre, Trivandrum, Trivandrum, India

Poster Presentations

LYS-P-35

Prognostic role of neutrophil and lymphocyte counts in primary nodal diffuse large-B-cell patients treated with Rituximab-CHOP immunochemotherapy

B. Spassov¹, Y. Georgieva, S. Nikolov, V. Madjarova, T. Dikov, G. Mihaylov, G. Balatzenko, M. Guenova

National Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria

LYS-P-36

Unusual coexistence of plasmablastic lymphoma and mature cystic teratoma of the ovary

I. Hadžisejdić¹, E. Babarović, L. Vranić, A. Duletić Načinović, K. Lučin, M. Krašević, N. Jonjić

Department of Pathology, Faculty of Medicine, ²Department of Haematology, University Hospital Centre, University of Rijeka, Rijeka, Croatia

LYS-P-37

Expression of costimulatory molecules on Hodgkin's lymphoma cells and modulation of T cell responses

A. M. Kursunel¹, S. Arslankoz², A. Uner¹, K. Gurbuz¹, D. Yoyen-Ermis¹, A. Uner², G. Esendagli¹

¹Department of Basic Oncology, Hacettepe University Cancer Institute, ²Department of Pathology, Hacettepe University Medical Faculty, ANKARA, Turkey

LYS-P-38

GATA-3 and c-MYC protein expression in Hodgkin lymphoma

J. Martin-Lopez¹, D. Garcia², Y. Vicente², I. Krsnik³, C. Bellas¹, P. Martin^{1,2}

¹Department of Pathology, ²Laboratory of Molecular Pathology, ³Department of Haematology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

LYS-P-39

Histiocytic sarcoma, clinicopathologic study of nine cases: single tertiary referral cancer center experience

S. Epari¹, V. S. Gadage, M. Deshmukh, S. Gujral, S. Laskar, M. Sengar, H. Menon, T. Shet
Tata Memorial Centre, Mumbai, India

LYS-P-40

Role of cytotoxic phenotype and microenvironment in angioimmunoblastic T-cell lymphoma (AITL)

T. Shet¹, S. Epari¹, M. Gupta¹, H. Jain², M. Sengar², H. Menon² and Adult hematolymphoid disease management group, Tata Memorial Hospital

¹Dept Of Pathology, ²Adult Hematolymphoid DMG, Tata Memorial Hospital, Mumbai, India

Poster Presentations

LYS-P-41

Evaluation of fluorescence based white blood cell extended parameters for screening and diagnosis of lymphomas

Z. H. Rana¹ and National institute of blood disease and bone marrow transplantation
Clinical Lab, National institute of blood disease and bone marrow transplantation, Karachi, Pakistan

LYS-P-42

Morphological types of high grade B-cell lymphoma

A. Kovrigina¹, E. Baryakh², T. Obukhova³, A. Misyurina⁴, S. Kravchenko⁴
¹pathology, National Research Center for Hematology, ²clinical hematology, Moscow City Hospital №52, ³lab. kariology, ⁴clinical hematology, National Research Center for Hematology, Moscow, Russian Federation

LYS-P-43

c-MYC evaluation in routine diagnostics – presentation of a work-flow and the experience with 248 cases of aggressive B-cell lymphomas

T. Menter^{1,2}, H. Medani¹, R. Ahmad¹, R. Flora¹, P. Trivedi¹, A. Reid¹, K. N. Naresh¹
¹Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS, London, United Kingdom, ²Pathology, University Hospital Basel, Basel, Switzerland

LYS-P-44

CD30 expression in NK/T cell extranodal lymphomas (NK/TC-EL) and their correlation with response to treatment and survival in an adult population of Mexico and Peru. Sociedad Latinoamericana de Hematopatología (SOLAHP)

C. Lome-Maldonado¹, C. M. Quezada-Fiallos¹, B. L. Acosta-Maldonado², R. Quezada-López³, I.-A. Montes-Mojarro⁴, D. Dueñas⁵, S. Casavilca⁶, G. Barboza⁷, A. Avilés⁸, C. Rojas-Cervantes¹, S. Rivas-Vera², C. Barrionuevo⁹, L. Quintanilla-Fend¹⁰
¹Pathology, Instituto Nacional de Cancerología, Mexico D.F., ²Hematology, Instituto Nacional de Cancerología, ³Pathology, Instituto Nacional de Cancerología, México D.F., Mexico, ⁴Pathology, University Hospital Tübingen, Tübingen, Germany, ⁵Pathology, ⁶Instituto Nacional de enfermedades neoplásicas, ⁷Pathology, Hospital María Auxiliadora, Lima, Peru, ⁸Pathology, Instituto Nacional de Cancerología, México D.F., Mexico, ⁹Pathology, Instituto Nacional de Enfermedades neoplásicas, Lima, Peru, ¹⁰Pathology, University hospital Tübingen, Tübingen, Germany

LYS-P-45

Primary cardiac lymphoma with secondary follicular lymphoma: case report and literature review

A. Kubodera¹, S. Ota¹, T. Yusuke², S. Emiko², N. Chiaki², N. Yukio¹
¹Pathology, ²Hematology, Chiba University Hospital, Chiba, Japan

Poster Presentations

LYS-P-46

Analysis of MYC, BCL2 and, BCL6 rearrangement in routine haematopathological diagnosis of aggressive B-cell lymphoma – a single centre study of 582 cases

H. Liu¹, R. Gahlaut², O. Giger³, G. Follows⁴, M. Scott¹, B. Matharu¹,
A. J. Watkins², S. Purdy⁵, J. W. Grant², P. Wright², H. El-Daly¹, M.-Q. Du³

¹Haematopathology and Oncology Diagnostic Service, ²Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, ³Department of Pathology, University of Cambridge, ⁴Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, ⁵Cellular Pathology Department, West Suffolk Hospital, Suffolk, United Kingdom

LYS-P-47

Lesions with infectious mononucleosis-like morphology in young solid organ transplant recipients: correlation with Epstein Barr viral load and outcome

M. O. Nakashima¹, C. V. Cotta

¹Laboratory Medicine, Cleveland Clinic, Cleveland, United States

LYS-P-48

Genome-wide analysis of plasmablastic lymphoma

I. Salaverrria¹, B. Gonzalez-Farre¹, J. E. Ramis-Zaldivar¹, S. Pack², A. Nicolae²,
G. Clot¹, A. Mottok³, H. Horn⁴, J. Y. Song², K. Fu⁵, G. Wright⁶, R. D. Gascoyne⁷,
W. C. Chan⁸, D. W. Scott⁷, R. M. Braziel⁹, E. B. Smeland¹⁰, L. M. Staudt¹¹,
A. Rosenwald¹², L. M. Rimsza¹³, G. Ott⁴, E. S. Jaffe², E. Campo¹ and for the
Leukemia and Lymphoma Molecular Profiling Project (LLMPP)

¹Hematopathology Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ²Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, United States, ³Centre for Lymphoid Cancer and Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada, ⁴Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, ⁵Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, ⁶National Cancer Institute, Bethesda, ⁷Centre for Lymphoid Cancer and Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, ⁸Department of Pathology, City of Hope National Medical Center, Duarte, ⁹Department of Clinical Pathology, Oregon Health & Science University, Oregon, United States, ¹⁰Department of Immunology and Centre for Cancer Biomedicine, University of Oslo and Oslo University Hospital, Oslo, Norway, ¹¹Lymphoid Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, United States, ¹²Department of Pathology, University of Wuerzburg, Wuerzburg, Germany, ¹³Department of Pathology, University of Arizona, Tucson, United States

Poster Presentations

LYS-P-49

The role of cannabinoid receptors in chemotaxis of mantle cell lymphoma

B. Sander*, M. Merrien, A. M. Wasik, B. Christensson

Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

LYS-P-50

The usefulness of LEF1 immunohistochemistry – routine working experience of two centres for haematopathology

T. Menter*^{1,2}, P. Trivedi¹, R. Ahmad¹, R. Flora¹, S. Dirnhofer², A. Tzankov², K. N. Naresh¹

¹Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS, London, United Kingdom, ²Pathology, University Hospital Basel, Basel, Switzerland

LYS-P-51

CD20-negative, non-plasmablastic diffuse large B-cell lymphoma: a rare aggressive lymphoma with frequent genetic alterations

E. Lakiotaki*¹, R. Chaireti², L. Saft¹, G. Z. Rassidakis¹

¹Pathology and Cytology, ²Hematology, Karolinska University Hospital, Stockholm, Sweden

LYS-P-52

B-cell lymphoma in Pakistan

A. Fatima*

MBBS, FJMU, Lahore, Pakistan

LYS-P-53

Frequency of mammary lymphomas in Pakistan

A. Fatima*

MBBS, FJMU, Lahore, Pakistan

LYS-P-54

Identifying the types of Non-Hodgkin lymphoma

A. Fatima*

MBBS, FJMU, Lahore, Pakistan

Poster Presentations

LYS-P-55

NanoString-based gene expression profiling distinguishes early- and advanced-stage follicular lymphoma

A. M. Staiger^{1,2}, H. Horn¹, E. Hofter³, V. Jurinovic³, S. Winter¹, E. Leich⁴, T. F. E. Barth⁵, H.-W. Bernd⁶, A. C. Feller⁶, K. Koch⁷, W. Klapper⁷, M. Hummel⁸, H. Stein⁹, D. Lenze⁸, M.-L. Hansmann¹⁰, S. Hartmann¹⁰, P. Möller⁵, M. Dreyling³, M. Engelhard¹¹, W. Hiddemann³, A. Rosenwald⁴, G. Ott²

¹Dr. Margarete Fischer Bosch Institute of Clinical Pharmacology, ²Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, ³Department of Internal Medicine, University of Munich, München, ⁴Universität Würzburg and Comprehensive Cancer Center Mainfranken (CCCMF), Institute of Pathology, Würzburg, ⁵Universitätsklinikum Ulm, Institute of Pathology, Ulm, ⁶Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Institute of Pathology, Lübeck, ⁷Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Institute of Pathology, Kiel, ⁸Campus Benjamin Franklin, Charité Universitätsmedizin, Institute of Pathology, ⁹Pathodiagnostik Berlin, Berlin, ¹⁰Universitätsklinikum Frankfurt, Institute of Pathology, Frankfurt, ¹¹University Hospital Essen, Department for Radiotherapy, Essen, Germany

LYS-P-56

Analysis of clinical feature, histological, immunophenotyping and cytogenetics in eight Mexican cases with De novo CD5+ diffuse large B-cell lymphoma

D. R. Quezada-López¹, L. Quintanilla-Fend², M. D. Nava¹, P. Santana¹, M. F. Hernández¹, R. Rivera¹, V. H. Olivera¹, C. Lome-Maldonado¹

¹Pathology, National Cancer Institute Mexico (INcan), Ciudad de Mexico, Mexico, ²Institut für Pathologie, Tübingen, Germany

LYS-P-57

Routine evaluation of MYC, IGH-BCL2 and BCL6 by FISH in DLBCL (2010-2015). A review of 324 cases: what have we learnt?

R. Meade¹, A. Green¹, M. Neat², N. Foot², D. Wrench³, P. Fields³, G. Mikhaeel⁴, B. Wilkins¹, J. D. van der Walt¹, M. Moonim¹

¹Cellular pathology, ²Cytogenetics, ³Clinical haematology, ⁴Clinical oncology, Guy's and St Thomas' NHS hospitals, London, United Kingdom

LYS-P-58

HHV-8-negative effusion-based large B-cell lymphoma presenting in the elderly: a rare, but distinct clinico-pathological entity

M. F. van den Hout¹, G. J. Timmers², M. J. Wondergem³, E. Barbé⁴, D. de Jong⁴

¹Pathology, azM/Maastricht UMC+, Maastricht, ²Hematology, Amstelland Ziekenhuis, Amstelveen, ³Hematology, ⁴Pathology, VU Universitij Medical Center, Amsterdam, Netherlands

Poster Presentations

LYS-P-59

Impact of follicular PD-1 and interfollicular CD10 expression in follicular lymphoma

A. Ruano*, J. Bodo, E. D. Hsi

Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, United States

LYS-P-60

Dynamics of MYC in (transformed) follicular lymphoma analyzed by immunohistochemistry and FISH

P. Kluin¹, S. Aukema^{2,3}, R. van Pel^{1,4}, I. Nagel^{3,5}, R. Siebert^{3,6}, S. Rosati¹, R. Kibbelaar⁷, M. Hoogendoorn⁸, G. van Imhoff⁴, H. Kluin-Nelemans⁴, M. Nijland⁴

¹Pathology and Medical Biology, ²University Medical Center Groningen, Groningen, Netherlands,

³Human Genetics, University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts

University Kiel, Kiel, Germany, ⁴Hematology, University Medical Center Groningen, Groningen,

Netherlands, ⁵Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-

Holstein, Campus Kiel, Kiel, ⁶Human Genetics, University of Ulm, Ulm, Germany, ⁷Pathology,

Pathologie Friesland, ⁸Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands

LYS-P-61

Morphometric analysis of neoplastic and non-neoplastic lymphoid infiltrate in endoscopic biopsies of gastric mucosa

S. Stojnev¹, M. Krstic^{1,2}, J. Todorovic³, M. Mladenovic³

¹Department of Pathology, Medical faculty, University of Nis, ²Center for Pathology, Clinical

center Nis, ³Medical faculty, University of Nis, Nis, Serbia

LYS-P-62

MYD88, CARD11 and CD79B mutations do not drive germinal center or activated B-cell phenotype of diffuse large B-cell lymphoma

A. Bal¹, V. Aggarwal¹, R. Srinivasan², G. Prakash³, P. Malhotra³, S. Varma³, A. Das¹

¹Department of Histopathology, ²Department of Cytology and Gynaecological Pathology,

³Department of Internal Medicine and Hemato-oncology, PGIMER, Chandigarh, India

Poster Presentations

LYS-P-63

Implementation of the National Register of lymphomas (RENALI) as the first bio-informatic platform in Mexico for hemato-oncological diseases

P. E. Santana-Vargas¹, R. D. Quezada-López², F. A. Grimaldo³, M. D. Nava², C. M. Quezada⁴, M. F. Hernández², L. P. Romero², A. Martínez², V. Méndez², S. Rivas³, A. Mohar⁵, C. Lome-Maldonado⁶, J. Bacou-Thedie⁷

¹*Servicio de Biología Molecular e Inmunopatología, Instituto de Cancerología, Ciudad de México,* ²*Patología,* ³*Servicio de Hematología, Hematología, Ciudad de Mexico, Mexico,* ⁴*Patología, Salud Integral Nicaragua, Managua, Nicaragua,* ⁵*Servicio de Epidemiología, Epidemiología,* ⁶*Servicio de Biología Molecular e Inmunopatología, Patología,* ⁷*Servicio de Informatica, Gooddata, Ciudad de Mexico, Mexico*

LYS-P-64

Whole exome sequencing for mutational profile of diffuse large B-cell lymphoma patients

A. Das¹, V. Aggarwal¹, R. Srinivasan², A. Bal¹, G. Prakash³, P. Malhotra³, S. Varma³

¹*Department of Histopathology,* ²*Department of Cytology and Gynaecological Pathology,* ³*Department of Internal Medicine and Hemato-oncology, PGIMER, Chandigarh, India*

LYS-P-65

Testicular blastic plasmocytoid dendritic cell neoplasm in 1 year-old-boy

J. Reszec¹, J. Dziecioł²

¹*Department of Medical Pathomorphology,* ²*Department of Human Anatomy, Medical University of Bialystok, Bialystok, Poland*

LYS-P-66

Quality improvement in determining genetic alterations in DLBCL with IQ SURE FISH probes. Therapeutic implications and comparative study with traditional probes

O. Balagué¹, A. Sierra, B. Gonzalez, E. Campo, A. Martínez

Pathology, Hospital Clinic. University of Barcelona, Barcelona, Spain

LYS-P-67

Plasmablastic lymphoma in stomach

J. Dziecioł¹, J. Reszec²

¹*Department of Human Anatomy, Medical University of Bialystok,* ²*Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland*

Poster Presentations

LYS-P-68

Silencer of cytokine signaling 1 gene is not silenced by DNA methylation in diffuse large B-cell lymphoma

J. K. Lennerz¹, S. E. Weissinger², U. Gerstenmaier³, R. Marienfeld², P. Möller^{1,2}

¹Department of Pathology and Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, United States, ²Institute of Pathology, University of Ulm, ³Varionostic, Ulm, Germany

LYS-P-69

Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center

I. Anagnostopoulos¹, R. U. Trappe², D. Lenze¹, M. Hummel¹, M. Pfreundschuh³, K. Jöhrens¹

¹Department of Pathology, Charité Universitätsmedizin Berlin, Berlin, ²Clinic for Internal Medicine II, DIAKO Bremen, Bremen, ³Medicine, Saarland University, Homburg, Germany

LYS-P-70

MYD 88 mutations in vitreous samples from patients with vitreoretinal B-cell lymphoma

J. Pawade¹, E. Carreno², L. Steeples², T. Clench¹, A. Dick²

¹Haematopathology, University Hospitals Bristol NHS Trust, ²Bristol Eye Hospital, Bristol, United Kingdom

LYS-P-71

Ipilimumab induced colitis: inflammation and subsequent tissue damage are the initial pathogenetic step in the development of EBV positive mucocutaneous ulcer

M. R. Pugh¹, M. Morgan², S. D. Dojcinov¹

¹All Wales Lymphoma Panel, ²Cellular Pathology, University Hospital of Wales, Cardiff, United Kingdom

LYS-P-72

HHV8 related aggressive B-cell lymphomas. A clinicopathological study in HIV and non-HIV patients

B. Gonzalez-Farre¹, M. Xipell², D. Martinez¹, E. Monclus², O. Balague¹, E. Gine³, L. Colomo⁴, E. Campo¹, A. Martinez¹

¹Pathology, ²Geriatrics, ³Hemathology, Hospital Clinic De Barcelona, ⁴Hemathology, Hospital del Mar, Barcelona, Spain

Poster Presentations

LYS-P-73

An unusual case of HHV8-negative effusion lymphoma: a case report – morphologically high-grade, clinically low-grade

M. Hosone¹, S. Arai¹, H. Katayama¹, Z. Naito²

¹Department of Pathology, Nippon Medical School Tama-Nagayama Hospital, ²Department of Pathology, Nippon Medical School, Tokyo, Japan

LYS-P-74

Unveiling another missing piece in EBV-driven lymphomagenesis: EBV-encoded miRNA expression in EBER-negative Burkitt lymphoma

L. Leoncini¹, L. Mundo¹, M. R. Ambrosio¹, M. Granai¹, L. del porro¹, M. Navari², G. de Falco¹, D. Gibellini³, P. P. Piccaluga²

¹University of Siena, Siena, ²University of Bologna, Bologna, ³University of Verona, Verona, Italy

LYS-P-75

STAT3 expression in diffuse large B-cell lymphoma of nodal and extranodal localization

M. Krstic^{1,2}, S. Stojnev¹, I. Petkovic³

¹Department for Pathology, Medical Faculty, University of Nis, ²Center for Pathology, ³Clinic for Oncology, Clinical Center Nis, Niš, Serbia

LYS-P-76

Signet-ring-cell variant of diffuse large B-cell lymphoma mimicking carcinoma

M. Krstic^{1,2}, S. Stojnev¹, L. Velickovic^{1,2}

¹Department for Pathology, Medical Faculty, University of Nis, ²Center for Pathology, Clinical Center Nis, Niš, Serbia

LYS-P-77

Utility of Cytogenetics: a case report determining between pediatric follicular lymphoma and diffuse large B-cell lymphoma

A. Duong¹, M. S. Stump¹, M. Hudspeth², J. J. Jarosca²

¹Pathology and Laboratory Medicine, ²Pediatric Hematology/Oncology, Medical University of South Carolina, Charleston, United States

LYS-P-78

Evaluation of Castleman disease with regard to HHV8 and EBV expression

S. Arslankoz¹, E. Ozhamam², A. Saglam³, A. H. Uner³

¹Pathology, Diskapi egitim ve arastirma hastanesi, ²Pathology, Ankara Numune egitim ve arastirma hastanesi, ³Pathology, Hacettepe, Ankara, Turkey

Poster Presentations

LYS-P-79

Burkitt lymphoma in adult: clinicopathologic study in a Peruvian population

D. Dueñas¹, A. la Rosa², S. Casavilca¹, G. Barboza³, J. de Anda⁴, S. Montes⁵, M. A. Piris⁵, C. Barrionuevo¹

¹Pathology, Instituto Nacional de Enfermedades Neoplásicas, ²Pathology, Instituto de Medicina Legal de Lima, ³Pathology, Hospital María Auxiliadora, Lima, Peru, ⁴Pathology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico, Mexico, ⁵Pathology, Hospital Universitario Marques de Valdecilla, Santander, Spain

LYS-P-80

miRNA sequencing unveils distinct molecular subgroups of plasmablastic lymphoma

P. P. Piccaluga¹, M. R. Ambrosio², S. Lazzi², L. Mundo², M. Picciolini³, M. Navari⁴, L. del Porro², T. Amato², C. Bellan², G. de Falco⁵, S. Ascani⁶, L. Leoncini²

¹Experimental, Diagnostic and Specialty Medicine, Bologna University, Bologna, ²Siena University, Siena, ³Diatech Pharmacogenetics, Jesi, ⁴Bologna University, Bologna, Italy, ⁵Queen Mary University of London, London, United Kingdom, ⁶Perugia-Terni University, Terni, Italy

Acknowledgements

The organizers of the 18th Meeting of the European Association for Haematopathology gratefully acknowledge the support of the following sponsors:

Platinum

Ventana Roche



Gold Sponsors

3DHISTECH



Silver Sponsors

Gilead Sciences Switzerland Sàrl

Celgene

Takeda Oncology



Bronze Sponsors

F. Hoffmann-La Roche Ltd
Illumina
NanoString Technologies

Seattle Genetics
Baxalta Schweiz AG

Other Sponsors

Dako Germany GmbH,
Milestone Srl,
Abbott GmbH & Co. KG,

Resolab Laborsysteme,
Shire



Sponsored Satellite Symposia

Saturday, September 3, 2016

6.30pm–7.30pm <i>San Francisco</i>	TAKEDA ONCOLOGY / SEATTLE GENETICS CD30 testing: an important step towards precision medicine in haematological malignancies
Chairs	<i>Stefano Pileri, (Bologna, Italy)</i> <i>Randy Gascoyne (Vancouver, Canada)</i>

Sunday, September 4, 2016

6.30pm–7.30pm <i>San Francisco</i>	CELGENE / NANOSTRING New Molecular Era of DLBCL - Cell-of-Origin Subtyping by Gene Expression Profiling and Clinical Implications
Chair	<i>Stephan Dirnhofer (Basel, Switzerland)</i>
	Introduction <i>Stephan Dirnhofer (Basel, Switzerland)</i>
	Scientific significance of COO and challenges with IHC <i>Elias Campo (Barcelona, Spain)</i>
	GEP determination of COO <i>David Scott (Vancouver, Canada)</i>
	Clinical significance and applications of COO in DLBCL <i>Annalisa Chiappella (Turin, Italy)</i>
	Close <i>Stephan Dirnhofer (Basel, Switzerland)</i>

Monday, September 5, 2016

1.30pm–2.30pm <i>San Francisco</i>	3DHISTECH Scientific and practical perspectives in digital hematopathology
Chair	<i>Isinsu Kuzu (Ankara, Turkey)</i>
	Digital diagnostics in hematopathology <i>András Matolcsy (Budapest, Hungary)</i>
	Digital pathology for training practical hematopathology <i>Isinsu Kuzu (Ankara, Turkey)</i>

Sponsored Satellite Symposia

	Digital pathologists' toolbox for fluorescent in situ hybridization slides scanning <i>Camille Franchet (Toulouse, France)</i>
5.00pm–6.30pm <i>San Francisco</i>	ILLUMINA Application of NGS in hematological malignancies
Chairs	<i>Philippe Gaulard (Paris, France)</i> <i>Richard Rosenquist (Uppsala, Sweden)</i>
	Genomic solutions for hematology <i>Claire Attwooll (California, USA)</i>
	Myeloid malignancies <i>Christian Thiede (Dresden, Germany)</i>
	Chronic lymphocytic leukemia <i>Elias Campo (Barcelona, Spain)</i>
	Aggressive lymphomas <i>Andreas Rosenwald (Wuerzburg, Germany)</i>
	Indolent lymphomas <i>Ming Du (Cambridge, UK)</i>
	Panel discussion

Tuesday, September 6, 2016

1.00pm–2.30pm <i>San Francisco</i>	VENTANA ROCHE Advances in immune cell immunohistochemistry: neoplastic and benign
	Application of new and critical immunohistochemical markers to malignant lymphomas arising in Malawi, Africa <i>Yuri Fedoriv (Chapel Hill)</i>
	Studies of the checkpoint immune system with new chromogenic multiplex assays <i>Teresa Marafioti (London UK)</i>

Networking Dinner

Tuesday, September 6, 2016

8.00pm – 11.00pm



Old Market Hall

The inviting aromas of fresh bread, sweet fruits and freshly ground coffee can once again be scented under the large cupola of the Old Market Hall. The attractive domed building has been in use as a market hall once again since October 2013, featuring market stalls well-stocked with fresh products and appetising menus. Eating, drinking and passing the time here is a unique occasion.

Address

Steinentorberg 20, 4051 Basel

How to Get There

The Old Market hall is within 2 minutes walking distance from the Main Train Station of Basel.

If arriving by tram take the line 1 or 8 and get off at the station “Markthalle”.

There are also plenty of parking spaces around the Old Market Hall.

Tickets

€100 per ticket including buffet and drinks

For Package registrations and accompanying person tickets are included, if you are marked to participate.

General Information

Registration

The registration desk is situated on the 2nd floor.

Registration Opening Hours

Saturday, September 3	12.30pm – 9.30pm
Sunday, September 4	6.45am – 7.30pm
Monday, September 5	6.45am – 7.00pm
Tuesday, September 6	6.45am – 7.30pm
Wednesday, September 7	8.00am – 6.00pm
Thursday, September 8	7.30am – 5.00pm

Congress Venue

Congress Center Basel
MCH Messe Basel
Messeplatz 21
4058 Basel, Switzerland

Abstract Publishing

Abstracts will be published online in an eBook available at www.eahp2016.com.

Catering

The catering stations for the coffee and lunch breaks are located in the exhibition on 2nd floor. Lunch and coffee breaks are included in the registration fee.

Certificate of Attendance

You may download your certificate of attendance after the congress.

Cloakroom

The cloakroom is situated on the ground level at the entrance.

Cloakroom Opening Hours

Saturday, September 3	12.30pm – 9.30pm
Sunday, September 4	6.45am – 8.00pm
Monday, September 5	6.45am – 7.00pm
Tuesday, September 6	6.45am – 7.30pm
Wednesday, September 7	8.00am – 6.00pm
Thursday, September 8	7.30am – 5.00pm

There is no overnight service available.

CME Accreditation

The 18th EAHP Meeting was granted **31** European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). CME certificates may be downloaded directly from the EAHP website for processing with the national authority in your country of practice.

European “CME” credits can be converted to the US CME Credits. Please visit the website of American Medical Association www.ama-assn.org

Helpful Numbers

Ambulance: 144

Fire service: 118

Police: 117

Taxi: +41 61 222 22 22

Exhibition Hours

Saturday, September 3 1:00pm – 9:00pm

Sunday, September 4 8:30am – 6:30pm

Monday, September 5 8:30am – 6:30pm

Tuesday, September 6 8:30am – 4:00pm

Internet – WiFi

Free WIFI will be available at the congress venue.

You may log-in with the following info:

SSID: EAHP_2016_Basel

UserID: 2692802816

Password: 1130

Please ensure the wireless connection on your device is enabled and your device is correctly protected for wireless usage. No technical support will be provided.

Language

The official language of the congress is English. Simultaneous translation will not be provided.

Media Check

The media check is located in room Nairobi on the 2nd floor. Speakers are requested to hand in their presentations (including all media files and embedded fonts) on a USB-stick at least 2 hours before their talk. Speakers having a presentation during the first time slot in the morning are asked to hand in their slides the day before. Technicians will assist with the upload of your files and provide the opportunity to preview and/or edit the presentation if necessary. Please allow enough time for potential trouble shooting. If you are unavoidably delayed, you must still go directly to the media check. All presentations must be run via the central media system. Personal laptops cannot be connected to it.

Media Check Opening Hours

Saturday, September 3	12.30pm – 7.00pm
Sunday, September 4	6.45am – 7.00pm
Monday, September 5	6.45am – 7.00pm
Tuesday, September 6	6.45am – 7.00pm
Wednesday, September 7	8.00am – 6.00pm
Thursday, September 8	7.30am – 3.30pm

Name Badges

The name badge will be the official ticket and should be worn at all times in order to access meeting rooms and exhibition halls. In case of lost or forgotten badges an administration fee of € 10 will be charged.

Program Changes

The organizer reserves the right to make changes if necessary. No full or partial refunds are made to the attendees in the event of cancellations or other changes in the program. Please note that changes will be posted at the registration desk and at the entrance of the session halls.

Photography, Audio, Video and Mobile Phone Policy

Audio, photo and video recording by any device (e.g. cameras, laptops, PDAs, mobile phones, watches) is strictly prohibited during all oral and poster sessions, unless prior permission is obtained from the congress organizer. Mobile phones must be in silent mode while attending sessions.

Travel Information

By Public Transport

Basel public transport (BVB) links up many areas and places. The dense Basel public transport network and the reliable timetable offer an ideal opportunity to explore Basel by means of the public transport service.

If you take tram no. 1 or 2, you can reach Congress Center Basel from the Swiss or French (SBB/SNCF) railway station in 10 minutes or from the German (DB) station (Badischer Bahnhof) in 5 minutes by tram no. 2 or 6.

Additional information concerning public transport can be found:

www.bvb.ch/en/news/current-info

Mobility Ticket

Each guest staying in a hotel in Basel, receives a Mobility Ticket upon check-in. This allows free use of the public transportation system in the city of Basel and its environs (zones 10, 11, 13 and 15, incl. the way to and from the Airport). The ticket is valid for max. 30 days. On the day of arrival, the reservation confirmation from the hotel guarantees a free transfer by public transport from the train station or the EuroAirport. So please don't forget to print your hotel confirmation and to take it with you on the tram or bus!


By Car

Basel is the point where the Swiss, French and German motorway networks meet. Messe Basel and the trade-fair grounds have their own motorway exit. The "Messe" exit from the A2 motorway leads directly to the fair and congress ground. There is a multi-storey car park with space for 1,300 vehicles at Exhibition Square.

Please bear in mind that you have to buy the official highway toll label ("Vignette") before using any motorway in Switzerland (more information at **www.vignette.ch**).

Travel to Basel

Travel to Basel Exhibition



MCH Messe Basel

GPS:
 Parking Messe Basel
 Riehenstrasse 101
 CH-4058 Basel

Visitors:
 Messeplatz
 CH-4058 Basel




No QR-Code Reader?
 Download at App-Store.



MCH Swiss Exhibition (Basel) Ltd. | CH-4005 Basel
 info@messe.ch | www.messe.ch

Overview Conference Venue



List of Exhibitors

Exhibitor sorted by alphabetical order	Booth No.
3DHISTECH Kft.	10
Abbott AG	08
Dako Germany GmbH	04
Milestone Srl	03
Resolab Laborsysteme	15
Takeda Oncology	07
Ventana Medical	01

WEIL ES SO NICHT GEHT ...

GIBT ES ZYDELIG®



JETZT KASSENZULÄSSIG
Erster zugelassener, oraler, selektiver
PI3K δ -Inhibitor bei CLL¹ und FL¹

Gekürzte Fachinformation ZYDELIG®

ZUS: Filmtabletten zu 150 mg/100 mg Idelalisib. **IND:** In Kombination mit Rituximab zur Behandlung von Patienten mit chronischer lymphatischer B-Zell Leukämie (B-CLL) und Komorbidität, die mindestens eine Vortherapie erhalten haben oder bei Hochrisiko-CLL-Patienten (17p-Deletion, TP53-Mutation), die für eine Chemioimmuntherapie ungeeignet sind. Als Monotherapie zur Behandlung von Patienten mit rezidivierendem follikulärem Lymphom (FL), die zwei vorausgegangene Therapielinien erhalten haben. **DOS:** 150 mg zweimal täglich unabhängig von den Mahlzeiten **KI:** Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe; bei akuter Hepatitis. **VM:** Im Falle erhöhter Transaminase-Werte, Diarrhö/Colitis und Pneumonitis. Verstärkte Überwachung der Patienten mit Leberfunktionsstörung. Vorsicht bei Patienten mit aktiver Hepatitis, schweren viralen Infektionen, Lebendimpfstoffen. Potentielles Risiko einer Phototoxizität. Keine Untersuchung in Kombination mit hormonellen Verhütungsmitteln. **IA:** Mögliche verminderte Wirksamkeit in Kombination mit CYP3A-Induktoren; mögliche erhöhte Serumkonzentration von anderen Arzneimitteln, die durch CYP3A metabolisiert werden; gleichzeitige Anwendung mit CYP3A4-Substraten mit geringer therapeutischer Breite oder CYP3A4-Substraten, die mit schwerwiegenden und/oder lebensbedrohlichen unerwünschten Wirkungen in Verbindung gebracht werden, sollte vermieden werden; mögliches Risiko einer verminderten Exposition sowie eine dadurch verminderte Wirksamkeit der Substrate induzierbarer Enzyme wie CYP2C9, CYP2C19, CYP2B6 und UGT; mögliche P-gp-Hemmung im Gastrointestinaltrakt. **UAW:** Pneumonie, Infektion der oberen Atemwege, Neutropenie, Anämie, Thrombozytopenie, erhöhte Triglyzeride, verminderter Appetit, Kopfschmerzen, Schlaflosigkeit, Husten, Dyspnoe, Rückenschmerzen, Gelenkschmerzen, Diarrhö, Übelkeit, Erbrechen, Obstipation, Bauchschmerzen, Colitis, erhöhte Transaminasen, Exanthem, Nachtschweiss, Pyrexie, Schüttelfrost, periphere Ödeme. **P:** 1 Flasche mit 60 Filmtabletten. **Abgabekategorie:** A. **ZUL:** Gilead Sciences Switzerland Sàrl, Postadresse: Turmstrasse 28, 6300 Zug. Ungekürzte Fachinformation unter www.swissmedinfo.ch. CH-GS-1501-1502D

Referenz 1 Fachinformation ZYDELIG®, Stand Januar 2015. www.swissmedinfo.ch



Gilead Sciences Switzerland Sàrl
Turmstrasse 28, CH-6300 Zug, www.gilead.com

Zydelig®
(idelalisib)

Imprint

Editors

European Association for Haematopathology

Local Congress Chair 2016

Professor Stephan Dirnhofer
Basel, Switzerland

Legal Organizer (PCO)

MCI Deutschland GmbH
MCI – Berlin Office
Markgrafenstrasse 56
10117 Berlin, Germany
eahp2016@mci-group.com

Congress Website

www.eahp2016.org

Graphic Design

R. Serinek | fgl-werketage.de

Print House

Lehmann Offsetdruck GmbH

Date of Publishing

August 12, 2016

The programme indicated may be subject to change.

EAHP2018

19th MEETING OF THE EUROPEAN ASSOCIATION FOR HAEMATOPATHOLOGY


www.eahp2018.com

Picture credit: © surangaw - Fotolia.com

SAVE THE DATE

Edinburgh, Scotland, UK
29 September – 4 October 2018

 **Local Organiser**
John Goodlad
Haematological Malignancy
Diagnostic Service (HMDS)
St James's University
Hospital Leeds, UK

 **Congress Venue**
Edinburgh International
Conference Centre
The Exchange Edinburgh,
150 Morrison St
Edinburgh, UK

 **Legal Organiser & PCO**
MCI Deutschland GmbH
Markgrafenstrasse 56
10117 Berlin, GER
☎ +49 30 204590
☎ +49 30 2045950
✉ eahp@mci-group.com



For further information please visit
www.eahp2016.com